CoviTrem1: TREM-1 Pathway Activation in COVID-19
Study Details
Study Description
Brief Summary
Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will develop acute respiratory failure, leading to their admission in Intensive Care Unit. There are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on myeloid and endothelial cells. Its activation leads to endothelial activation and damage, hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction.
We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- prognostic value of the TREM-1 pathway activation on clinical worsening [day 28]
Eligibility Criteria
Criteria
Inclusion Criteria Consecutive COVID-19 hospitalized patients for less than 3 days
Exclusion Criteria:
No consent Pregnancy protected populations
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHRU Limoges | Limoges | France | 87042 | |
| 2 | Central hospital | Nancy | France |
Sponsors and Collaborators
- Central Hospital, Nancy, France
- University Hospital, Limoges
- Inotrem
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020PI120